336 related articles for article (PubMed ID: 27649838)
41. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.
Matsuo T; Yamasaki O
Clin Case Rep; 2017 May; 5(5):694-700. PubMed ID: 28469878
[TBL] [Abstract][Full Text] [Related]
42. Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction.
Laroche A; Alarcon Chinchilla E; Bourgeault E; Doré MA
J Cutan Med Surg; 2018; 22(6):627-629. PubMed ID: 29772919
[TBL] [Abstract][Full Text] [Related]
43. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
Crosson JN; Laird PW; Debiec M; Bergstrom CS; Lawson DH; Yeh S
J Immunother; 2015; 38(2):80-4. PubMed ID: 25658618
[TBL] [Abstract][Full Text] [Related]
44. Recurrent anterior uveitis in patients with Vogt-Koyanagi-Harada syndrome.
Taylor S; Lightman S
Arch Ophthalmol; 2004 Jun; 122(6):922-3. PubMed ID: 15197072
[No Abstract] [Full Text] [Related]
45. Nivolumab-induced neuralgic amyotrophy with hourglass-like constriction of the anterior interosseous nerve.
Porambo ME; Sedarsky KE; Elliott EJ; Theeler BJ; Smith JK
Muscle Nerve; 2019 Jun; 59(6):E40-E42. PubMed ID: 30809822
[No Abstract] [Full Text] [Related]
46. Nivolumab-induced myositis: A case report and a literature review.
Bourgeois-Vionnet J; Joubert B; Bernard E; Sia MA; Pante V; Fabien N; Honnorat J; Streichenberger N
J Neurol Sci; 2018 Apr; 387():51-53. PubMed ID: 29571871
[No Abstract] [Full Text] [Related]
47. Case of acute-onset type 1 diabetes induced by long-term immunotherapy with nivolumab in a patient with mucosal melanoma.
Maekawa T; Okada K; Okada H; Kado S; Kamiya K; Komine M; Murata S; Oka K; Ishibashi S; Ohtsuki M
J Dermatol; 2019 Dec; 46(12):e463-e464. PubMed ID: 31436330
[No Abstract] [Full Text] [Related]
48. Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
Ansorge C; Seufert J; Meiss F; von Bubnoff D
J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30411844
[No Abstract] [Full Text] [Related]
49. Programmed cell death 1 blockade-induced cutaneous sarcoid-like epithelioid granulomas in advanced melanoma: a case report.
Ogawa T; Ishitsuka Y; Iwamoto K; Koguchi-Yoshioka H; Tanaka R; Watanabe R; Fujisawa Y; Fujimoto M
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e260-e261. PubMed ID: 29314333
[No Abstract] [Full Text] [Related]
50. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.
Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S
Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288
[No Abstract] [Full Text] [Related]
51. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
Korman AM; Tyler KH; Kaffenberger BH
Int J Dermatol; 2017 Apr; 56(4):e75-e77. PubMed ID: 28102540
[No Abstract] [Full Text] [Related]
52. Nivolumab-induced Limbic Encephalitis with Anti-Hu Antibody in a Patient With Advanced Pleomorphic Carcinoma of the Lung.
Matsuoka H; Kimura H; Koba H; Tambo Y; Ohkura N; Hara J; Sone T; Kasahara K
Clin Lung Cancer; 2018 Sep; 19(5):e597-e599. PubMed ID: 29857970
[No Abstract] [Full Text] [Related]
53. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
Facchinetti F; Gnetti L; Caruana P; Fornaroli F; Luigi de'Angelis G; Sabato M; Ferri L; Cosenza A; Bordi P; Tiseo M
Clin Lung Cancer; 2018 Sep; 19(5):e591-e596. PubMed ID: 29801705
[No Abstract] [Full Text] [Related]
54. Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.
Callens R; Tamsin A; van Zandweghe L
J Thorac Oncol; 2019 Mar; 14(3):e49-e50. PubMed ID: 30782382
[No Abstract] [Full Text] [Related]
55. Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
Bricout M; Petre A; Amini-Adle M; Bezza W; Seve P; Kodjikian L; Dalle S; Thomas L
J Immunother; 2017; 40(2):77-82. PubMed ID: 28166182
[TBL] [Abstract][Full Text] [Related]
56. Histologically-diagnosed psoriasiform dermatitis induced by nivolumab successfully controlled by etanercept: A case report.
Kim YE; Kim TM; Jo SJ
J Dermatol; 2019 Dec; 46(12):e464-e466. PubMed ID: 31531885
[No Abstract] [Full Text] [Related]
57. Profiling human leukocyte antigens in Vogt-Koyanagi-Harada syndrome.
Zhang XY; Wang XM; Hu TS
Am J Ophthalmol; 1992 May; 113(5):567-72. PubMed ID: 1575232
[TBL] [Abstract][Full Text] [Related]
58. Acute demyelinating polyneuropathy induced by nivolumab.
Fukumoto Y; Kuwahara M; Kawai S; Nakahama K; Kusunoki S
J Neurol Neurosurg Psychiatry; 2018 Apr; 89(4):435-437. PubMed ID: 28844069
[No Abstract] [Full Text] [Related]
59. Nivolumab-associated bullous pemphigoid reactions involving multiple epitopes.
Aoki Y; Miyagawa F; Miyashita K; Nishimura Y; Hashimoto T; Asada H
Eur J Dermatol; 2019 Oct; 29(5):552-554. PubMed ID: 31570326
[No Abstract] [Full Text] [Related]
60. Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma.
Cinotti E; Fiorani D; Provvidenziale L; Miracco C; Calamai V; Danielli R; Rubegni P
Int J Dermatol; 2019 Jul; 58(7):e138-e140. PubMed ID: 30810218
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
